Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Lifestyle Natural Medicines

Renaissance Technologies LLC Has $4.11 Million Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Renaissance Technologies LLC trimmed its position in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 28.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 3,313,833 shares of the biopharmaceutica

By: ETF Daily News

Oct 02 2024
122
9197 Views

Renaissance Technologies LLC Has $4.11 Million Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Renaissance Technologies LLC trimmed its position in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 28.3% during the second quarter, Holdings Channel.com reports. The institutional inve… [+3916 chars]

Related

Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

For Girls to Succeed in STEM, Confidence Matters as Much as Competence

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Average Price Target from Analysts

United Nations summit gives Indigenous groups voice on nature conservation decisions

Agreement signed at UN summit gives Indigenous groups voice

Can viruses cause cancer?

Exploring the hemp market: legal cannabinoids for relaxation and relief

Life in the Ruins

6 Expert-Recommended Vitamins and Minerals That Unlock Healthy Aging

The Third Atomic Bomb: Self-replicating RNA vaccines

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Next

Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate